Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus ZINACEF IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus ZINACEF IN PLASTIC CONTAINER.
CEFIZOX vs ZINACEF IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
750 mg intravenously or intramuscularly every 8 hours; for severe infections, 1.5 g intravenously every 8 hours.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life is approximately 1.5 hours in adults with normal renal function; prolonged to 3-4 hours in neonates and up to 20-30 hours in end-stage renal disease.
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; the remainder is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic